Research Letter

Evaluation of Pretreatment Magnetic Resonance Elastography for the Prediction of Radiation-Induced Liver Disease

Trey C. Mullikin, MD,a,1 Kay M. Pepin, PhD,a,1 Jaden E. Evans, MD,b Sudhakar K. Venkatesh, MD,c Richard L. Ehman, MD,c Kenneth W. Merrell, MD,a Michael G. Haddock, MD,a William S. Harmsen, MS,d Michael G. Herman, PhD,a and Christopher L. Hallemeier, MDa,*

aDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; bDepartment of Radiation Oncology, Intermountain Health Care, Ogden, Utah; cDepartment of Radiology, Mayo Clinic, Rochester, Minnesota; dDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota

Received June 8, 2021; accepted August 26, 2021

Abstract

Purpose: Magnetic resonance (MR) elastography (E) is a noninvasive technique for quantifying liver stiffness (LS) for fibrosis. This study evaluates whether LS is associated with risk of developing radiation-induced liver disease (RILD) in patients receiving liver-directed radiation therapy (RT).

Methods and Materials: Based on prior studies, LS ≤ 3 kPa was considered normal and LS > 3.0 kPa as representing fibrosis. RILD was defined as an increase in Child-Pugh (CP) score of ≥ 2 from baseline within 1 year of RT. Univariate and multivariate Cox models were used to assess correlation.

Results: One hundred two patients, 51 with primary liver tumors and 51 with liver metastases, were identified with sufficient follow-up. In univariate models, pre-RT LS > 3.0 kPa (hazard ratio [HR] 4.9; 95% confidence interval [CI], 1.6-14; P = .004), body mass index (BMI), clinical cirrhosis, CP score, albumin-bilirubin (ALBI) grade 2, primary liver tumor, and mean liver dose were significantly associated with risk of post-RT RILD. In a multivariate analysis, LS > 3.0 and mean liver dose both were significantly associated with RILD risk.

Conclusions: Elevated pre-RT LS is associated with an increased risk of RILD in patients receiving liver-directed RT.

© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Sources of support: This study was supported with CTSA Grant UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. Additional support provided by NIH Grant EB001981, U.S. Department of Defense Grant W81XWH-19-1-0583-01, and Varian Medical Systems.

Disclosure: Dr Pepin reports employment at Resoundant, Inc. and is outside the realm of the submitted work. All other authors have no disclosures to declare.

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

*Corresponding author: Christopher L. Hallemeier, MD; E-mail: Hallemeier.Christopher@mayo.edu
1 T.C.M. and K.M.P contributed equally to this work.

https://doi.org/10.1016/j.adro.2021.100793
2452-1094/© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Before the development of advanced radiation delivery techniques, the risk of classic radiation-induced liver disease (RILD) limited the use of radiation therapy (RT) for the management of liver cancers.1,2 Risk of developing classic RILD is 5% to 35% when the entire liver is irradiated to 30 to 35 Gy; however, ablative doses are often necessary to achieve local tumor control.3,4 In the current era with image guided and ablative RT techniques, nonclassic RILD, which is more closely aligned with acute hepatic decompensation, remains a concern, has been typically evaluated by change in Child-Pugh (CP) score, and occurs in 3.6% to 31% of patients receiving either ablative or hypofractionated RT.4-8 Predictive criteria for RILD are not well established.9,10

MRE is a noninvasive technique for staging liver fibrosis with excellent reproducibility.11,12 In patients with chronic liver disease, elevated LS on MRE is associated with increased risk of hepatic decompensation, development of liver cancer, and death.13 A recent pilot study of 17 patients treated with stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) found pretreatment LS to be significantly higher in patients who developed RILD.10 We sought to further evaluate the role of MRE in predicting the risk of RILD in a larger population of patients receiving SBRT and hypofractionated RT for primary liver cancer and liver metastasis.

Methods and Materials

Study population

With institutional review board approval, we retrospectively analyzed a population of patients who received liver-directed RT at our institution between January 2010 and June 2018. Inclusion criteria were age ≥18 years, receipt of RT (≥30 Gy), MRE examination within 6 months before RT, and post-RT laboratory studies.

CP score and albumin-bilirubin (ALBI) score were calculated.14 The primary end point was cumulative incidence of RILD. RILD was defined as an increase in CP score ≥2 from baseline within 12 months of RT.1 For patients with liver metastasis without clinical diagnosis of cirrhosis, a baseline CP score of A5 was assigned (n = 18). RT parameters including treatment modality (protons or photons), dose and fractionation, gross tumor volume (GTV), total liver volume (liver-GTV), and tumor-to-liver ratio were recorded. For all patients, normal liver dose constraints for either TG101,15 NRG-GI003 (NCT03186898), or NCT009768982 were met. For calculation of equivalent dose in 2 Gy fractions (EQD2), an α/β, 10 for tumor dose was used and an α/β, 3 for mean liver dose was used.

Liver MRE

The majority of liver MREs were completed on a departmental Discovery 750-Watt MR imaging device (GE Healthcare, Chicago, IL) as a treatment position MR imaging for radiation planning. The liver MRE technique has been well described.16 Four axial slices were obtained through the largest cross-section of the liver. Mean liver parenchyma stiffness was calculated by averaging across manually drawn regions of interest, including only liver parenchyma, and measured by the reading radiologist. Based on previous studies, LS ≤3 kPa was considered normal and LS >3 kPa was consistent with the presence of fibrosis.16 Pre-RT liver MRE results for 2 patients are shown in Figure 1.

Statistical analysis

Analyses were conducted using SAS® version 9.4 (SAS Institute, Cary, NC). The cumulative incidence of RILD was estimated considering death and liver transplantation as competing risks. The Cox model was used to assess association of baseline variables with risk of RILD.

Results

We identified 103 patients, and 102 patients had post-treatment follow-up—51 with primary liver tumors and
51 with liver metastasis. The most common primary liver tumor was HCC (n = 42/51, 82%), and the most common origin of metastasis was colorectal (16/51, 30%). Table 1 describes the pre-RT characteristics. Mean pre-RT LS was 3.9 kPa (range 1.8, 8.7). Variables associated with increased baseline LS >3.0 were primary versus metastatic tumors (4.9 kPa vs 3.0 kPa, \( P < .0001 \)), CP score (A vs B/C, 3.9 kPa vs 5.2 kPa, \( P = .002 \)), ALBI score (per 1 point, \( P = .01 \)), and clinical cirrhosis (yes vs no, 5.2 kPa vs 3.1 kPa, \( P < .0001 \)).

Twenty-three patients developed RILD (23/102, 23%) at a median of 4 months post-RT. Seven patients died within 1 year of treatment without RILD. Two patients underwent liver transplantation, 1 of whom had developed RILD before liver transplantation. Mean pre-RT LS was 4.9 kPa versus 3.6 kPa for those who did versus did not develop RILD (\( P < .001 \)). For the entire cohort, the cumulative incidence of RILD at 6 months and 12 months post-RT was 26% (95% CI, 18-38) and 29% (95% CI, 21-42), respectively. The cumulative incidence of RILD at 6 and 12 months for pre-RT LS \( \leq \) 3.0 kPa was 12% (95% CI, 4.9-31) and 12% (95% CI, 4.9-31) and for pre-RT LS >3.0 kPa was 36% (95% CI, 24-43) and 41% (95% CI, 29-59), respectively (Fig 2).

Univariate Cox models identified several pre-RT variables associated with development of RILD (Table 2). Pre-RT LS >3.0 kPa was associated with an increased risk of post-RT RILD (HR 4.9; 95% CI 1.6-14.3; \( P = .004 \)) in overall analysis (Fig 2). Analysis was performed in patient subgroups of primary tumor versus metastasis and clinical diagnosis of cirrhosis (yes vs no) (Table 3). In these subgroups, the rate of RILD was higher for patients with LS >3 kPa (HR 2.4-2.9), although these associations were not statistically significant (all \( P > 0.05 \)).

Because there were only 23 RILD events, an initial multivariable model included 3 clinically relevant variables that were significantly associated with RILD in the univariable model: CP score (A vs B/C), dichotomized

Table 1  Pre–radiation therapy characteristics

| Variable                          | N or Mean (Range) |
|-----------------------------------|-------------------|
| Age (years)                       | 65 (30, 87)       |
| Sex                               |                   |
| Male                              | 62                |
| Female                            | 40                |
| BMI (kg/m²)                       | 28.3 (15.3, 47.2) |
| Primary liver cancer              | 51                |
| HCC                               | 42                |
| IHC                               | 6                 |
| GBC                               | 2                 |
| EHC                               | 1                 |
| Metastatic lesion origin          | 51                |
| Colorectal                        | 16                |
| Melanoma                          | 11                |
| Noncolorectal GI                  | 9                 |
| Hematological                     | 2                 |
| Genitourinary                     | 4                 |
| Gynecologic                       | 3                 |
| Breast                            | 2                 |
| Other*                            | 4                 |
| Cirrhosis etiology                |                   |
| HCV                               | 12                |
| HBV                               | 2                 |
| Alcohol                           | 10                |
| NASH                              | 9                 |
| Other†                            | 7                 |
| Child-Pugh Class‡                 |                   |
| A                                 | 28                |
| B                                 | 11                |
| C                                 | 1                 |
| Unknown                           | 11                |
| ALBI grade                        |                   |
| 1                                 | 49                |
| 2                                 | 31                |
| 3                                 | 4                 |
| Unknown                           | 18                |
| RT parameters                     |                   |
| GTV (cm³)                         | 144.5 (0.7, 3035) |
| Liver-GTV (cm³)                   | 1574 (811, 3079)  |
| Tumor-to-liver ratio (%)          | 5.75 (0.03, 71.6) |
| Total fractions <10≥10            | 79/23             |
| Photon/proton                     | 76/26             |
| Total dose (Gy)                   | 55.8 (30, 70)     |
| Total dose EGD2 (Gy)              | 92.4 (40, 150)    |
| Mean liver dose (Gy)              | 11.5 (1.71, 25.1) |
| Mean liver EGD2 (Gy)              | 11.3 (1.10, 28.9) |
| Post-RT systemic therapy          | 20                |
| Liver stiffness (kPa)              |                   |
| \( \leq 3.0 \) kPa / > 3.0 kPa    | 43/59             |

Abbreviations: BMI = body mass index; EHC = extrahepatic cholangiocarcinoma; EQD2 = equivalent dose in 2 Gy fractions; GBC = gall bladder carcinoma; GTV = gross tumor volume; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IHC = intrahepatic cholangiocarcinoma; NASH = nonalcoholic steatohepatitis; RT = radiation therapy.

* Other metastatic lesions include adrenocortical carcinoma, thymoma, oropharynx cancer, and salivary duct cancer.
† Other etiologies include autoimmune hepatitis, alpha-1-antitrypsin, hemochromatosis, and cryptogenic cirrhosis.
‡ For patients with cirrhosis.

Figure 2 Cumulative incidence of radiation-induced liver disease in patients stratified by baseline liver stiffness. LS ≤ 3.0 kPa or LS > 3.0 kPa (hazard ratio 4.9; 95% confidence interval, 1.6-14.3; \( P = .004 \)). Abbreviations: LS = liver stiffness.
pre-RT LS (≤3.0 vs >3.0), and continuous mean liver dose. This model included 84 patients (18 had missing CP scores); LS >3.0 (P = .041) and mean liver dose (P = .046) were associated with RILD, while CP score was not (P = .38). The final model included all 102 patients, and both variables were significantly associated with RILD risk, LS >3.0 (HR 5.0; CI, 1.7-14.8; P = .004) and mean liver dose (HR 1.08 per 1 Gy; CI, 1.01-1.2; P = .04) with concordance score 0.75.

Discussion

In this cohort of patients who received liver-directed RT, elevated pre-RT LS measured by MRE was associated with an increased risk of developing RILD. In the context of a known hepatic malignancy or metastasis, increased LS likely demonstrates a liver compromised by fibrosis with reduced hepatic reserve. Our results are

Table 2  Univariate models for survival-free RILD after RT

| Variable | No RILD (n = 79) | RILD (n = 23) | Hazard Ratio | 95% CI | P value |
|----------|-----------------|--------------|--------------|-------|--------|
| Age (>65 years) | 65.0 (30-87) | 64.3 (42-87) | 0.6 | 0.23-1.33 | 0.19 |
| Sex Male/Female | | | | | |
| Male | 48 | 13 | 0.9 | 0.37-1.93 | 0.69 |
| Female | 31 | 9 | | | |
| BMI (kg/m²) | 27.6 (15.3-47.2) | 30.5 (18.6-42.9) | | | |
| Per 1 point | 1.1 | 1.001-1.54 | 0.047 |
| BMI < 25 | 1.0 (ref) | | | | |
| 25 ≤ BMI < 30 | 1.4 | 0.37-5.14 | 0.63 |
| 30 ≤ BMI < 35 | 3.4 | 1.07-10.9 | 0.04 |
| BMI ≥ 35 | 3.1 | 0.79-12.6 | 0.11 |
| Liver Function | | | | | |
| Normal | 55 | 7 | | | |
| Clinical cirrhosis | 24 | 16 | 5.0 | 2.03-12.2 | <0.001 |
| Child-Pugh Score* | | | | | |
| Per 1 point | 1.5 | 1.06-2.04 | 0.02 |
| Child-Pugh A | 51 | 16 | | | |
| Child-Pugh B/C | 10 | 7 | 2.0 | 0.81-4.76 | 0.14 |
| ALBI grade | | | | | |
| Per 1 point | 2.1 | 1.16-3.78 | 0.01 |
| ALBI grade 1 | 44 | 2 | | | |
| ALBI grade 2 | 16 | 14 | 4.6 | 1.66-13.0 | 0.003 |
| ALBI grade 3 | 2 | 2 | 2.9 | 0.56-15.1 | 0.20 |
| Liver tumor characteristics | | | | | |
| Metastasis | 47 | 4 | 1.0 (ref) | | |
| Primary | 32 | 19 | 5.1 | 1.73-15.0 | 0.003 |
| Gross tumor volume (cm³) per 100 cm³ | 152.0 (7.3-3034) | 119 (4.4-928) | 0.97 | 0.85-1.10 | 0.60 |
| Liver-GTV (cm³) per 100 cm³ | 1555 (865-3079) | 1640 (811-2747) | | | |
| Tumor-to-liver ratio >0.02 | 0.06 (0.0003-0.72) | 0.06 (0.003-0.33) | 2.4 | 0.93-5.97 | 0.07 |
| Parameters of RT | | | | | |
| Total number of fractions, ≤5 | 64 | 16 | 1.0 (ref) | | |
| Total number of fractions, >10 | 15 | 7 | 1.5 | 0.61-3.67 | 0.37 |
| Photon-based RT | 59 | 17 | | | |
| Proton-based RT | 20 | 6 | 0.9 | 0.36-2.30 | 0.83 |
| Total dose (Gy), per 10 Gy | 55.5 (45-67.5) | 56.7 (30-70) | 1.3 | 0.67-2.35 | 0.48 |
| Mean liver dose (Gy), per 1 Gy | 10.2 (1.7-23.4) | 13.4 (3.4-22.8) | 1.1 | 1.001-1.2 | 0.047 |
| Mean liver dose (Gy) EQD2, per 1 Gy | 10.4 (1.2-27.4) | 13.7 (2.5-28.9) | 1.9 | 0.999-3.61 | 0.05 |
| Post-RT systemic therapy | 18 | 2 | 2.4 | 0.57-10.4 | 0.23 |
| Liver stiffness (kPa) | 3.6 (1.8-8.7) | 4.9 (2.1-8.6) | 1.3 | 1.07-1.56 | 0.009 |
| Per 1 kPa | 4.9 | | | 1.64-14.3 | 0.004 |

Results expressed as mean (range).

Abbreviations: ALBI = albumin-bilirubin; BMI = body mass index; CI = confidence interval; EQD2 = equivalent dose in 2 Gy fractions; RILD = radiation induced liver disease; RT = radiation therapy.

* For patients with metastasis and no signs of cirrhosis, a CP score of A5 was assigned.
consistent with those of Ichikawa et al, who found that elevated pre-RT LS was associated with a higher risk of RILD in a cohort of 17 patients with HCC undergoing SBRT. Our study expands on this report with a larger cohort of patients with primary liver tumors, patients with liver metastasis, and those treated with hypofractionated RT techniques, and the inclusion of both photon-based and proton-based regimens.

Our evaluation supports multiple clinical and dosimetry factors that have previously been associated with an increased risk of developing RILD. These include pretreatment BMI, CP score, ALBI grade 2, primary liver tumor, and normal liver dose constraints. Additionally, we found that RT prescription dose, fractionation schedule, and RT modality (proton vs photon) were not associated with the development of RILD. An exploratory analysis in subgroups of patients with primary liver tumor vs metastasis and clinical diagnosis of cirrhosis (yes vs no) suggested higher rates of RILD in patients with elevated LS in all subgroups. However, associations were not statistically significant, perhaps due to small numbers of events and patients.

MRE is an attractive technique for assessing risk of RILD because it is noninvasive, reproducible, objective, and convenient for patients who require an MR evaluation for assessment and/or RT planning. Other novel imaging techniques are being explored for pretreatment assessment of patients with liver tumors and/or metastasis, including sulfur colloid single photon emission computed tomography, indocyanine green clearance on MR, and Eovist® (Bayer, Whippany, NJ) enhancement on MR. One significant development is the use of ALBI grade instead of CP score for prediction of RILD and overall survival. Compared with CP score, which requires subjective assessment of encephalopathy and ascites and is impacted by the use of warfarin, ALBI grade relies on only objective measures and has been shown to be more predictive of overall survival and RILD than CP score.

Limitations of the study include the retrospective nature of data collection and analysis and a heterogeneous cohort in terms of patient and treatment characteristics. For measurement of RILD, we applied change in CP score to noncirrhotic patients as has been done in other series, although this has not been rigorously evaluated. Moreover, we considered change in ALBI score for a measure of liver dysfunction as well; however, only 43 patients had sufficient information, limiting analysis and utility. Finally, the overall sample size and number of RILD events limits our multivariate model in determining the most significant independent factors associated with development of RILD.

### Conclusion

Elevated pre-RT LS measured by MRE was associated with an increased risk of RILD as measured by change in CP score in patients receiving SBRT and hypofractionated RT for primary liver tumors and liver metastasis. Further work is needed to validate whether MRE has independent predictive ability for RILD, incorporating other known risk factors.

### References

1. Chapman TR, Bowen SR, Schaub SK, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: Defining clinically relevant endpoints. *Pract Radiat Oncol*. 2018;8:157–166.

2. Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. *Semin Radiat Oncol*. 2018;28:321–331.
3. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the lyman ntcp model. *Int J Radiat Oncol Biol Phys*. 2002;53:810–821.

4. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepaticcellular carcinoma. *J Clin Oncol*. 2013;31:1631–1639.

5. Dyk P, Weiner A, Badiyan S, et al. Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the child-pugh score classification system. *Pract Radiat Oncol*. 2015;5:176–182.

6. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol*. 2016;34:460–468.

7. Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. *Pract Radiat Oncol*. 2015;5:e443–e449.

8. Nabavizadeh N, Waller JG, Fain 3rd R, et al. Safety and efficacy of accelerated hypofractionation and stereotactic body radiation therapy for hepatocellular carcinoma patients with varying degrees of hepatic impairment. *Int J Radiat Oncol Biol Phys*. 2018;100:577–585.

9. Liang S-X, Zhu X-D, Xu Z-Y, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. *Int J Radiat Oncol Biol Phys*. 2006;65:426–434.

10. Ichikawa S, Motosugi U, Oguri M, et al. Magnetic resonance elastography for prediction of radiation-induced liver disease after stereotactic body radiation therapy. *Hepatology*. 2017;66:664–665.

11. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: Technique, analysis, and clinical applications. *J Magn Reson Imaging*. 2013;37:544–555.

12. Yin M, Glaser KJ, Talwalkar JA, et al. Hepatic MR elastography: Clinical performance in a series of 1377 consecutive patients. *Radiology*. 2016;278:114–124.

13. Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2013;11:1573–1584.

14. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach with the Albi grade. *J Clin Oncol*. 2015;33:550–558.

15. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM task group 101. *Med Phys*. 2010;37:4078–4101.

16. Venkatesh SK, Ehman RL. Magnetic resonance elastography of liver. *Magn Reson Imaging Clin N Am*. 2014;22:433–446.

17. Bowen SR, Chapman TR, Borgman J, et al. Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. *EJNMMI Res*. 2016;6:57.

18. Suresh K, Owen D, Bazzi L, et al. Using indocyanine green extraction to predict liver function after stereotactic body radiation therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2018;100:131–137.

19. Wang H, Feng M, Jackson A, et al. Local and global function model of the liver. *Int J Radiat Oncol Biol Phys*. 2016;94:181–188.

20. Murray LJ, Sykes J, Brierley J, et al. Baseline albumin-bilirubin (ALBI) score in Western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT). *Int J Radiat Oncol Biol Phys*. 2018;101:900–909.

21. Su TS, Yang HM, Zhou Y, et al. Albumin-bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. *Radiat Oncol*. 2019;14:50.